Korea Insight Signal

  Eli Lilly closed at USD 1,220.28 on the US market on 12 August 2026. Applied to trailing twelve-month earnings per share, that gives a price-to-earnings ratio of about 41.0. A ratio of 41 is neither expensive nor cheap on its own. What it means depends on the growth it assumes. This article takes that assumption apart: where the revenue comes from, what raises it and what erodes it, and which conditions would have to fail for the assumption to break down. Table of Contents What Eli Lilly's Valuation Assumes The Structure and Requirements of the Tirzepatide Business What the Revenue Data Shows The Conditions That Keep the Growth Premium in Place How Eli Lilly Differs From Novo Nordisk Limits of the Investment Case Frequently Asked Questions Summary 1. What Eli Lilly's Valuation Assumes The price-to-earnings ratio divides the share price by earnings per share. The closing price of USD 1,220.28 on 12 August 2026 and trailing twelve-month earnings per share of US...

  Novo Nordisk is a Danish pharmaceutical company that has worked on diabetes treatment for more than a century. The reason it came to be valued as a very different kind of company during the 2020s is that one class of medicine, the GLP-1 receptor agonists, expanded from diabetes into obesity and then into cardiovascular risk reduction. Yet the second-quarter 2026 results show a gap: the products are selling well, while growth for the company as a whole is low. This article examines where that gap comes from. Rather than listing figures, it follows the structure through which revenue growth is actually produced. Table of Contents Why the GLP-1 Business Was Built This Way The Structure and Requirements of the Wegovy Range What the Second-Quarter 2026 Data Shows The Core Mechanism Behind Revenue Growth How Eli Lilly's Structure Differs Limitations of the Current Business Structure Frequently Asked Questions Summary 1. Why the GLP-1 Business Was Built This Way Semagl...